ML22095A285
| ML22095A285 | |
| Person / Time | |
|---|---|
| Site: | 05000232, 03020372 |
| Issue date: | 04/05/2022 |
| From: | Latischa Hanson Division of Nuclear Materials Safety IV |
| To: | Document Control Desk |
| References | |
| License-627275-165144 | |
| Download: ML22095A285 (1) | |
See also: IR 05000232/2014001
Text
NRC FORM 374 PAGE 1 OF 3 PAGES
U.S. NUCLEAR REGULATORY COMMISSION Amendment No. 24
MATERIALS LICENSE
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I,
Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued
authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s)
and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This
license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and
orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.
Licensee In accordance with letter dated 4. Expiration Date: March 31, 2025
July 6, 2021
1. Diagnostic Health Center of Anchorage, LLC
A wholly owned subsidiary of Alliance HealthCare
Services
5. Docket No.: 030-20372
2. 4100 Lake Otis Parkway #102 3. License No.: 50-23214-01 is Reference No.:
Anchorage, AK 99508 amended in its entirety to read as
follows:
6. Byproduct, source, 7. Chemical and/or physical form 8. Maximum amount that licensee 9. Authorized use
and/or special nuclear may possess at any one time
material under this license
A. Any byproduct material A. Any A. As Needed A. For use in uptake, dilution and
permitted by 10 CFR excretion studies permitted by 10 CFR
35.100 35.100.
B. Any byproduct material B. Any B. As Needed B. For use in imaging and localization
permitted by 10 CFR studies permitted by 10 CFR 35.200.
35.200
C. Iodine-131 C. Any C. 500 millicuries total C. Any sodium iodide Iodine-131 use
permitted by 10 CFR 35.300 for which
the patient can be released under the
provisions of 10 CFR 35.75.
D. Any byproduct material D. Prepackaged Kits D. 50 millicuries total D. For use in in-vitro studies.
permitted by 10 CFR
31.11
NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 2 OF 3 PAGES
License No.: 50-23214-01 Docket or Reference No.:
MATERIALS LICENSE 030-20372
SUPPLEMENTARY SHEET Amendment No. 24
CONDITIONS
10. Licensed material may be used only at the licensees facilities located at Lake Otis Medical Plaza, 4100 Lake Otis Parkway #102,
Anchorage, Alaska.
11. The Radiation Safety Officer for this license is Kay Kassel, MS, CNMT.
12. Licensed material shall only be used by, or under the supervision of:
A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
B. The following individuals are authorized users for the material and medical uses as indicated:
Authorized Users Material and Use
Marc R. Beck, M.D. 35.100; 35.200; Oral administration of sodium iodide I-131; 31.11
Robert L. Bridges, M.D. 35.100; 35.200; Oral administration of sodium iodide I-131; 31.11
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the
minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 3 OF 3 PAGES
License No.: 50-23214-01 Docket or Reference No.:
MATERIALS LICENSE 030-20372
SUPPLEMENTARY SHEET Amendment No. 24
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements,
representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to
those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the
licensees ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory
Commissions regulations shall govern unless the statements, representations, and procedures in the licensees application and
correspondence are more restrictive than the regulations.
A. Application dated October 20, 2014 (ML14336A723)
B. Letter dated February 16, 2015 with enclosures (ML15061A178)
C. Letter dated July 6, 2021 (ML21196A052)
FOR THE U.S. NUCLEAR REGULATORY COMMISSION
Digitally signed by Latischa M.
Latischa M. Hanson Hanson
April 5, 2022 Date: 2022.04.05 19:20:39 -05'00'
Date: By:
Latischa M. Hanson
Region IV